Literature DB >> 20882602

Inhibition of hypoxia-inducible transcription factor complex with designed epipolythiodiketopiperazine.

Swati Kushal1, Hui Wang, Csaba F László, Lajos Z Szábo, Bogdan Z Olenyuk.   

Abstract

Designed small molecule inhibitors of hypoxia-inducible gene expression have potential to become new research tools for molecular biology, genetics and serve as leads to new therapeutics. We report design, synthesis evaluation of biological activity, and a preliminary mechanistic study of epipolythiodiketopiperazine (ETP) transcriptional antagonist that targets the interaction between the C-terminal transactivation domain (C-TAD) of hypoxia-inducible factor 1α (HIF-1α) and cysteine-histidine rich region (CH1) of transcriptional coactivator p300/CBP. Our results indicate that in cultured cells synthetic ETP 3 disrupts the structure and function of this complex in a dose-dependent manner, resulting in rapid downregulation of hypoxia-inducible gene expression. 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20882602     DOI: 10.1002/bip.21550

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  5 in total

1.  Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling.

Authors:  Swati Kushal; Brooke Bullock Lao; Laura K Henchey; Ramin Dubey; Hanah Mesallati; Nathaniel J Traaseth; Bogdan Z Olenyuk; Paramjit S Arora
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-09       Impact factor: 11.205

2.  Synthesis and Anticancer Activity of Epipolythiodiketopiperazine Alkaloids.

Authors:  Nicolas Boyer; Karen C Morrison; Justin Kim; Paul J Hergenrother; Mohammad Movassaghi
Journal:  Chem Sci       Date:  2013-04-01       Impact factor: 9.825

3.  Inhibition of the HIF1α-p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II).

Authors:  Madura K P Jayatunga; Sam Thompson; Tawnya C McKee; Mun Chiang Chan; Kelie M Reece; Adam P Hardy; Rok Sekirnik; Peter T Seden; Kristina M Cook; James B McMahon; William D Figg; Christopher J Schofield; Andrew D Hamilton
Journal:  Eur J Med Chem       Date:  2014-06-27       Impact factor: 6.514

4.  A novel function of novobiocin: disrupting the interaction of HIF 1α and p300/CBP through direct binding to the HIF1α C-terminal activation domain.

Authors:  Donglu Wu; Rui Zhang; Rui Zhao; Guang Chen; Yong Cai; Jingji Jin
Journal:  PLoS One       Date:  2013-05-06       Impact factor: 3.240

5.  Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.

Authors:  Kelie M Reece; Emily D Richardson; Kristina M Cook; Tessa J Campbell; Stephen T Pisle; Alesia J Holly; David J Venzon; David J Liewehr; Cindy H Chau; Douglas K Price; William D Figg
Journal:  Mol Cancer       Date:  2014-04-28       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.